BCM
MGNX icon

Bridgeway Capital Management’s MacroGenics MGNX Stock Holding History

Bridgeway Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Sell
73,500
-7,700
-9% -$16.4K ﹤0.01% 1022
2025
Q4 		$131K Sell
81,200
-7,500
-8% -$11.8K ﹤0.01% 1093
2025
Q3 		$149K Sell
88,700
-45,000
-34% -$72.8K ﹤0.01% 1055
2025
Q2 		$162K Buy
133,700
+18,500
+16% +$26.8K ﹤0.01% 1004
2025
Q1 		$146K Buy
115,200
+11,200
+11% +$29.3K ﹤0.01% 979
2024
Q4 		$338K Buy
+104,000
New +$375K 0.01% 898

Other funds holding MGNX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bridgeway Capital Management's MGNX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its MacroGenics (MGNX) stake by 9.5% in Q1 2026, selling an estimated $16.4K and leaving 73,500 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Bridgeway Capital Management first reported a position in MGNX in Q4 2024 and has held it in 6 quarters since. The position peaked at $338K in Q4 2024. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

  • Bridgeway Capital Management held 73,500 shares of MacroGenics worth $212K as of Q1 2026.
  • Bridgeway Capital Management sold 7,700 MacroGenics shares in Q1 2026, an estimated $16.4K.
  • MacroGenics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1022 holding.
  • Bridgeway Capital Management first reported a position in MacroGenics in Q4 2024 and has held it in 6 quarters since.
  • Bridgeway Capital Management's MacroGenics position peaked at $338K in Q4 2024.
  • 109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.